Another tentative factor that might influence the treatment outcome is the ability of higher doses of GLP-1R agonist to cause nausea (49)
Always follow your healthcare providers instructions on using these medications in combination for the best results
Access this article Similar content being viewed by others References Correale M, Leopizzi A, Mallardi A, Ranieri A, Suriano MP, DAlessandro D, Tricarico L, Mazzeo P, Tucci S, Pastore G, Maulucci G, Di Biase M, Brunetti ND (2020) Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation
Weight Loss Efficacy Mazdutide Phase 3 GLORY-2 demonstrated 20.1% weight loss at 60 weeks, exceeding survodutide's Phase 2 on-treatment result of 18.7%
Longer courses may require dose adjustments or temporary changes to either medication